We are Pioneers.
We bridge AI and Life Sciences to open new horizons.
We shift the paradigm in AI.
We think differently and we tackle significant unmet societal needs.
Science and Innovation is our DNA, which makes us a unique company.
The way we do change the status quo is by making our platform beautifully designed and user friendly.
We have in place an exceptionally skilled and agile team.
We have developed the innov’SAR platform for our partners.
What makes PEACCEL different is that it can produce massive amounts of new data to train its ML/DL platform.
Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality.
The innov’SAR core approach is interpolative, extrapolative and predicts out-of-the-box, not found in other state-of-the-art ML / DL.
It can screen 1 Billion mutants per day.
PEACCEL is definitely the only company capable of fully capturing epistasis and predicting outside the box, we are ahead of competition especially in terms of “hit rate”.
- We have developed the “innov’SAR” PLATFORM, including 4 modules :
- 15 PUBLICATIONS in peer reviewed journals in less than 2 years
- 3 PATENTS (including 2 on our technology using FFT), with more to come
- Robust PARTNERSHIPS with top notch KOLs worldwide
- Focus on high value PRODUCTS
- Highly skilled PEOPLE in high tech fields
PEACCEL is managed by a seasoned multi national team accumulating scientific, business and management experienced in chemical, pharmaceutical and biotech industry. The company operates in Paris (France) and Cambridge (MA, USA).
Creation Date: 2011
Chief Executive Officer : Laurent Contaut
Industrial Field : Artificial Intelligence, Machine Learning, Deep Learning, Biotechnology, Pharmaceuticals, Chemistry